Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Assets (2022 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Other Non-Current Assets for 4 consecutive years, with $743000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 22.28% year-over-year to $743000.0, compared with a TTM value of $743000.0 through Sep 2025, down 22.28%, and an annual FY2024 reading of $822000.0, up 0.74% over the prior year.
  • Other Non-Current Assets was $743000.0 for Q3 2025 at Fennec Pharmaceuticals, down from $768000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.0 million in Q1 2024 and bottomed at $14000.0 in Q2 2022.
  • Average Other Non-Current Assets over 4 years is $548928.6, with a median of $755500.0 recorded in 2025.
  • The sharpest move saw Other Non-Current Assets skyrocketed 833.02% in 2024, then dropped 22.35% in 2025.
  • Year by year, Other Non-Current Assets stood at $211000.0 in 2022, then skyrocketed by 286.73% to $816000.0 in 2023, then grew by 0.74% to $822000.0 in 2024, then decreased by 9.61% to $743000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for FENC at $743000.0 in Q3 2025, $768000.0 in Q2 2025, and $794000.0 in Q1 2025.